Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Sip and ScpB are highly conserved among strains of Group B Streptococcus (GBS). Thus, the two proteins are attractive antigens for inclusion in a vaccine against GBS. In this study, we constructed and expressed the two proteins, and investigated their specific mucosal immune responses against GBS induced by intranasal immunization with cholera toxin (CT) and CpG-oligodeoxynucleotides (CpG-ODNs). Intranasal immunization with different doses of recombinant Sip and ScpB all elicited specific antibodies in serum and vagina of mice. A combination of rSip and rScpB with either CT or CpG-ODN elicited specific antibodies in serum and vaginal samples. Th1 responses were enhanced by CpG and CT. Sera from the mice group intranasally immunized with rSip+CT, rScpB+CT, rSip+rScpB+CT, and rSip+rScpB+CpG also showed bactericidal activity compared with the serum of the control group. The current findings suggest that rSip and rScpB would be useful antigens as a vaccine component to induce protective immune responses against GBS, and CpG-ODN could be used as an effective mucosal adjuvant in inducing a good mucosal immune response. The use of an intranasal vaccine composed of different surface protein antigens is an attractive strategy for the development of a vaccine against GBS.
Xue
Guanhua
G
Beijing Children's Hospital, Capital Medical University, Beijing, China.
Yu
Lihua
L
Li
Shentao
S
Shen
Xuzhuang
X
D018829:Adhesins, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D001769:Blood / Q000276:immunology; D001770:Blood Bactericidal Activity; D002772:Cholera Toxin / Q000008:administration & dosage; D010450:Endopeptidases / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013292:Streptococcus agalactiae / Q000276:immunology*; D014611:Vaccination / Q000379:methods; D014621:Vagina / Q000276:immunology
D018829:Adhesins, Bacterial; D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; C414463:SIP protein, Streptococcus group B; D022541:Streptococcal Vaccines; D002772:Cholera Toxin; D010450:Endopeptidases; C053088:C5a peptidase